Please assess the completion status of the following clinical trial:

Trial Title: Curcumin for the Prevention of Radiation-induced Dermatitis in Breast Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female with a diagnosis of, non-inflammatory breast adenocarcinoma and be referred for post-operative radiotherapy without concurrent chemotherapy.~* Participants must be at least 21 years of age.~* Participants must not be pregnant.~* Participants can be from any racial or ethnic origin.~* Breast adenocarcinoma could have been treated by either lumpectomy or mastectomy with or without adjuvant or neoadjuvant chemotherapy or hormonal treatment.~* Participants with in situ breast cancer are eligible.~* Participants who are prescribed concurrent hormone treatment with radiation treatment are eligible.~* Participants must be scheduled to receive five sessions of radiation therapy per week (1 session per day) for at least four weeks using standard (1.8-2.0 Gy per session)or Canadian (2.2-2.5 Gy per session)irradiation fractionation.~* A time period of three weeks must elapse after chemotherapy and surgery before beginning the study.~* The total dose prescribed to the whole breast should be 50 Gy or greater.~* Participants must be able to understand English and able to complete assessment forms (all assessment forms are in English).~* Participants must be able to swallow medication.~* Topical skin agents, e.g., Aquaphor, Cetaphil, or other emollients, are allowed either PRN or prophylactically.~* Participant must give informed consent.~Exclusion Criteria:~* Patients with bilateral breast cancer are not eligible.~* Patients who have had previous radiation therapy to the breast or chest are not eligible.~* Patients who are prescribed chemotherapy concurrently with radiation treatment are not eligible.~* Patients who will be receiving treatment with Herceptin (trastuzumab), anti-coagulants, or anti-human epidermal growth factor receptor (EGFR) drugs, e.g. Iressa (gefitinib), Erbitux (cetuximab, C225), concurrently with their radiation therapy are not eligible.~* Patients cannot have had breast reconstructions, implants, and/or expanders.~* Patients with known radiosensitivity syndromes (e.g., Ataxia-telangiectasia) are not eligible.~* Patients with collagen vascular disease, vasculitis, unhealed surgical sites, or breast infections are not eligible.~* Patients whose baseline blood tests meet the following criteria are not eligible: greater than or equal to Grade 2 change Hemoglobin (i.e., 25% decrease from baseline); greater than or equal to Grade 1 change in Platelets (i.e., less than 75,000/mm3); greater than or equal to Grade 2 change in PT and PTT(i.e., 1.5-2x upper level normal (ULN)); greater than or equal to Grade 1 change in AST, ALT (i.e., greater than 2.5x ULN); greater than or equal to Grade 1 change in Bilirubin (i.e., greater than 1.5x ULN); greater than or equal to Grade 1 change in Creatinine (i.e., greater than 2x ULN).

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Curcumin C3 Complex (Type: ACTIVE_COMPARATOR): Patients take 2.0 grams curcumin (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (\~4-7 weeks).
- Placebo (Type: PLACEBO_COMPARATOR): Patients take 2.0 grams placebo (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (\~4-7 weeks).

Based on this trial design, predict the completion outcome and termination type (if applicable).